<?xml version='1.0' encoding='utf-8'?>
<document id="23322139"><sentence text="Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive."><entity charOffset="29-40" id="DDI-PubMed.23322139.s1.e0" text="albiglutide" /><entity charOffset="98-105" id="DDI-PubMed.23322139.s1.e1" text="digoxin" /><entity charOffset="107-115" id="DDI-PubMed.23322139.s1.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.23322139.s1.e0" e2="DDI-PubMed.23322139.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23322139.s1.e0" e2="DDI-PubMed.23322139.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23322139.s1.e0" e2="DDI-PubMed.23322139.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23322139.s1.e1" e2="DDI-PubMed.23322139.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23322139.s1.e1" e2="DDI-PubMed.23322139.s1.e2" /></sentence><sentence text="Albiglutide is a glucagon-like peptide-1 analog that is currently under investigation for the treatment of type 2 diabetes mellitus as a once-weekly injection"><entity charOffset="0-11" id="DDI-PubMed.23322139.s2.e0" text="Albiglutide" /></sentence><sentence text=" Three open-label phase 1 studies were conducted in healthy human participants to investigate potential pharmacokinetic (PK) and/or pharmacodynamic (PD) interactions between albiglutide and medications that may be used concomitantly" /><sentence text="" /><sentence text="Digoxin 0"><entity charOffset="0-7" id="DDI-PubMed.23322139.s5.e0" text="Digoxin" /></sentence><sentence text="5 mg, warfarin 25 mg, or a standard, low-dose oral contraceptive containing norethindrone (NE) 0"><entity charOffset="76-89" id="DDI-PubMed.23322139.s6.e0" text="norethindrone" /><entity charOffset="91-93" id="DDI-PubMed.23322139.s6.e1" text="NE" /><pair ddi="false" e1="DDI-PubMed.23322139.s6.e0" e2="DDI-PubMed.23322139.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23322139.s6.e0" e2="DDI-PubMed.23322139.s6.e1" /></sentence><sentence text="5 mg and ethinyl estradiol (EE) 0"><entity charOffset="9-26" id="DDI-PubMed.23322139.s7.e0" text="ethinyl estradiol" /><entity charOffset="28-30" id="DDI-PubMed.23322139.s7.e1" text="EE" /><pair ddi="false" e1="DDI-PubMed.23322139.s7.e0" e2="DDI-PubMed.23322139.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23322139.s7.e0" e2="DDI-PubMed.23322139.s7.e1" /></sentence><sentence text="035 mg were administered alone and after steady-state albiglutide exposure (50 mg weekly for 4-5 weeks)" /><sentence text=" The lack of a drug-drug interaction was concluded if the 90% CIs of geometric least-squares means ratio of area under the curve and maximum concentration were fully contained within 0" /><sentence text="80 to 1" /><sentence text="25" /><sentence text=" The effects of albiglutide on the PD of warfarin (international normalized ratio) and on the PD of a low-dose oral contraceptive (luteinizing hormone [LH], follicle-stimulating hormone [FSH], and progesterone) were assessed"><entity charOffset="16-27" id="DDI-PubMed.23322139.s12.e0" text="albiglutide" /><entity charOffset="197-209" id="DDI-PubMed.23322139.s12.e1" text="progesterone" /><pair ddi="false" e1="DDI-PubMed.23322139.s12.e0" e2="DDI-PubMed.23322139.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23322139.s12.e0" e2="DDI-PubMed.23322139.s12.e1" /></sentence><sentence text=" Safety and tolerability were also assessed" /><sentence text="" /><sentence text="Overall, the PK profiles of digoxin, warfarin, NE, and EE were unaffected by albiglutide administration; standard bioequivalence criteria were met with a few exceptions that were not considered clinically relevant"><entity charOffset="28-35" id="DDI-PubMed.23322139.s15.e0" text="digoxin" /><entity charOffset="37-45" id="DDI-PubMed.23322139.s15.e1" text="warfarin" /><entity charOffset="47-49" id="DDI-PubMed.23322139.s15.e2" text="NE" /><entity charOffset="55-56" id="DDI-PubMed.23322139.s15.e3" text="EE" /><pair ddi="false" e1="DDI-PubMed.23322139.s15.e0" e2="DDI-PubMed.23322139.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23322139.s15.e0" e2="DDI-PubMed.23322139.s15.e1" /><pair ddi="false" e1="DDI-PubMed.23322139.s15.e0" e2="DDI-PubMed.23322139.s15.e2" /><pair ddi="false" e1="DDI-PubMed.23322139.s15.e0" e2="DDI-PubMed.23322139.s15.e3" /><pair ddi="false" e1="DDI-PubMed.23322139.s15.e1" e2="DDI-PubMed.23322139.s15.e1" /><pair ddi="false" e1="DDI-PubMed.23322139.s15.e1" e2="DDI-PubMed.23322139.s15.e2" /><pair ddi="false" e1="DDI-PubMed.23322139.s15.e1" e2="DDI-PubMed.23322139.s15.e3" /><pair ddi="false" e1="DDI-PubMed.23322139.s15.e2" e2="DDI-PubMed.23322139.s15.e2" /><pair ddi="false" e1="DDI-PubMed.23322139.s15.e2" e2="DDI-PubMed.23322139.s15.e3" /></sentence><sentence text=" Warfarin international normalized ratio was unaffected by albiglutide administration" /><sentence text=" No clinically meaningful differences in LH, FSH, or progesterone were observed"><entity charOffset="45-48" id="DDI-PubMed.23322139.s17.e0" text="FSH" /><entity charOffset="53-65" id="DDI-PubMed.23322139.s17.e1" text="progesterone" /><pair ddi="false" e1="DDI-PubMed.23322139.s17.e0" e2="DDI-PubMed.23322139.s17.e0" /><pair ddi="false" e1="DDI-PubMed.23322139.s17.e0" e2="DDI-PubMed.23322139.s17.e1" /></sentence><sentence text=" Most treatment-emergent adverse events were mild, and all resolved by study end" /><sentence text="" /><sentence text="Based on tolerability and the lack of clinically significant PK or PD interactions, no dose adjustments should be required when albiglutide is administered concomitantly with these medications" /><sentence text="" /></document>